Why does the Inner-Helix Mutation A413C Double the Stoichiometry of Kv1.3 Channel Block by Emopamil but not by Verapamil?

Alexey Rossokhin*, Tobias Dreker*, Stephan Grissmer#, and Boris S. Zhorov#

Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada (AR, BSZ); Research Centre of Neurology, Russian Academy of Medical Sciences, Moscow (AR); Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg (BSZ); 4SC AG, Planegg-Martinsried, Germany (TD); Institute of Applied Physiology, Ulm University, Ulm, Germany (SG).
Running title: Kv1.3 block by Phenylalkylamines

Address correspondence to:

Boris S. Zhorov, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada. Tel. (905) 525-9140 x. 22049. FAX 905-522-9033.
E-mail: zhorov@mcmaster.ca

Number of text pages: 22 (including Title, Running Title, and Abstract pages)
Number of tables: 2
Number of figures: 8
Number of references: 51
Number of words in the Abstract: 247
Number of words in the Introduction: 1250
Number of words in Discussion: 1125

Abbreviations: MC, Monte Carlo; MCM, Monte-Carlo minimization;
Abstract

hKv1.3 channels in lymphocytes are targets for chemotherapy of autoimmune diseases. Phenylalkylamines block Kv1.3 channels by poorly understood mechanisms. In the inactivation-reduced mutant H399T, the second mutation A413C in S6 substantially decreases potency of phenylalkylamines with a para-methoxy group at the phenylethylamine end, whereas potency of phenylalkylamines lacking this group is less affected. Intriguingly, completely demethoxylated emopamil blocks mutant H399T/A413C with a 2:1 stoichiometry. Here we generated a triple mutant H399T/C412A/A413C and found that its emopamil-binding properties are similar to those of the double mutant. These data rule out disulfide bonding Cys412-Cys413, which would substantially deform the inner-helix, suggest a clash of Cys413 with the para-methoxy group, and provide a distance constraint to dock phenylalkylamines in a Kv1.2-based homology model. Monte Carlo-minimizations predict that the verapamil ammonium group donates an H-bond to the backbone carbonyl of Thr391 at the P-loop turn, the pentanenitrilephenyl moiety occludes the pore, while the phenylethylamine meta- and para-methoxy substituents approach, respectively, the sidechains of Met390 and Ala413. In the double-mutant model, the Cys413 sidechains accept H-bonds from two emopamil molecules whose phenyl rings fit in the hydrophobic inter-subunit interfaces, while the pentanenitrilephenyl moieties occlude the pore. Since these interfaces are unattractive for a methoxylated phenyl ring, the ammonium group of respective phenylalkylamines cannot approach the Cys413 sidechain and binds at the focus of P-helices, while the para-methoxy group clashes with Cys413. Our study proposes an atomistic mechanism of Kv1.3 block by phenylalkylamines and highlights the intra- and inter-subunit interfaces as ligand-binding loci.
Introduction

Potassium channels play fundamental roles in physiology (Hille, 2001), being targets for chemotherapy of cardiovascular, neurological, autoimmune, and other disorders (Chandy et al., 2004; Tamargo et al., 2004; Wulff and Zhorov, 2008). Kv1.3 channels are involved in the activation of T lymphocytes and therefore play an important role in the immune activity (Chandy et al., 1984; DeCoursey et al., 1984). Verapamil, which belongs to the class of phenylalkylamines, blocks Kv1.3 channels with low micromolar concentration (DeCoursey, 1995; Dreker and Grissmer, 2005; Jacobs and DeCoursey, 1990; Rauer and Grissmer, 1996; Rauer and Grissmer, 1999). Verapamil was originally identified as an antagonist of L-type calcium channels in the heart and vascular smooth muscles (Pelzer et al., 1982; Wit and Cranefield, 1974). Later verapamil was found to block potassium channels in neurons (Kostyuk et al., 1975), lymphocytes (DeCoursey et al., 1985) and other tissues. Phenylalkylamines have a flexible alkylamine chain flanked by aromatic rings, A and B that are proximal, respectively, to the isopropyl and amino groups in the chain (Fig. 1). The amino group of verapamil is predominantly protonated at physiological pH (Retzinger et al., 1986). A permanently charged derivative of verapamil, N-methyl-verapamil, acts from the intracellular but not the extracellular side and the channel opening is required for the drug to reach its binding site (DeCoursey, 1995; Rauer and Grissmer, 1996; Zhang et al., 1999). The rate of the K⁺ current block by the externally applied verapamil increases with the external pH (DeCoursey, 1995; Zhang et al., 1999) indicating that verapamil crosses the lipid membrane in the deprotonated form and reaches the receptor from the cytoplasm.

Block of Kv1.3 by externally applied phenylalkylamines resembles state-dependent block of the squid potassium channels by internally applied quaternary ammonium compounds (DeCoursey, 1995), which are known to block the intracellular vestibule of potassium...
channels (Armstrong, 1971; Armstrong and Hille, 1972). Compounds that block Kv1.3 at the extracellular vestibule such as kaliotoxin, charybdotoxin, and extracellular tetraethylammonium do not compete with verapamil in blocking of K⁺ current (Rauer and Grissmer, 1996; Rauer and Grissmer, 1999). However, internal application of the N-methyl-verapamil or tetraethylammonium in combination with verapamil revealed competition for the channel block (Rauer and Grissmer, 1996; Rauer and Grissmer, 1999). Thus, several lines of evidence suggest that verapamil and internally applied quaternary ammonium drugs have overlapping binding sites in the inner pore region.

Kv1.3 is formed by four identical subunits. Each subunit contains six membrane-spanning segments and a membrane re-entering P-loop. The pore region is formed by the outer (S5) and inner (S6) helices connected by the P-loop. The latter includes the pore helix (P), the ascending limbs with the signature-sequence VGYG whose backbone carbonyls line the selectivity filter, and the extracellular linker between the ascending limb and S6. In the x-ray structures of bacterial and mammal potassium channels (Doyle et al., 1998; Jiang et al., 2002; Long et al., 2005) several interfaces between the pore-forming alpha-helical segments are seen. Four interfaces are lined by S6s from neighbouring subunits. In homology models of sodium and calcium channels corresponding interfaces between domains III and IV contain residues whose mutations affect access and binding of different ligands (Bruhova et al., 2008; Cheng et al., 2009; Tikhonov and Zhorov, 2008; Zhorov and Tikhonov, 2004). Extracellularly applied permanently charged compounds, which cannot permeate the membrane, were proposed to reach their binding sites within the inner pore through the III/IV domain interface (Bruhova et al., 2008; Tikhonov et al., 2006; Tikhonov and Zhorov, 2008). Some ligands of the Kv1.5 channel were also proposed to reach their binding site via the intersubunit interface (Strutz-Seebohm et al., 2007). Since the experimental evidences for the existence of such a pathway in Kv channels are limited, we use the term “niche” to indicate
that the interface is reachable for certain moieties of some ligands from the inner pore (Wulff and Zhorov, 2008). Besides the intersubunit niches, potassium channels have intrasubunit niches lined by S6 and P-helices. Although the intrasubunit niches are rather narrow in the x-ray structures, they contain ligand-sensing residues. Thus, mutation M\textsuperscript{47I} (see Fig. 2A for residue labels) decreases the tetraethylammonium potency more than 50-fold (Choi et al., 1993).

Dreker and Grissmer (2005) found that in the background of the H\textsuperscript{56T} mutation with the reduced slow inactivation, the second mutation A\textsuperscript{11C} substantially decreases potency of verapamil and other phenylalkylamines with a \textit{para}-methoxy group in ring B, whereas the potencies of phenylalkylamines lacking this group are less sensitive to the mutation (Dreker and Grissmer, 2005). Intriguingly, among several tested phenylalkylamines only emopamil and only in the A\textsuperscript{11C} mutant demonstrates the Hill coefficient of two for the channel block (Dreker and Grissmer, 2005). The rationale for these observations is unclear. Thus, the bulky sidechain of C\textsuperscript{i11} can sterically obstruct the ligand binding. Besides, since the hydrophobicity index of cysteine is similar to that of valine (Nagano et al., 1999), the SH group of C\textsuperscript{i11} would make the phenylalkylamine receptor more hydrophobic. On the other hand, the proximity of the engineered C\textsuperscript{i11} and the native C\textsuperscript{i10} suggests that the sidechains of these two residues could be linked by a disulfide bond. Such a bond would deform the inner helix that lines the inner pore where phenylalkylamines ligands are expected to bind.

To explore whether the mutation A\textsuperscript{11C} affects phenylalkylamine block due to local changes at the upper third of the inner helix or due to the inner pore deformation upon possible C\textsuperscript{i10}-C\textsuperscript{i11} disulfide bonding, we generated here a triple mutant H\textsuperscript{56T}/C\textsuperscript{i10}A/A\textsuperscript{11C} and demonstrated that its emopamil-binding properties are similar to those of the double mutant H\textsuperscript{56T}/A\textsuperscript{11C}. These data strongly suggest that the effect of mutation A\textsuperscript{11C} on the ligand binding is due to direct interaction of the engineered cysteine with the ligands. Furthermore,
the fact that phenylalkylamines with the para-methoxy group in ring B are most sensitive to
the A^{11}C mutation suggests that the para-methoxy group approaches the A^{11} sidechain in the
wildtype channel, thus providing an important distance constraint to dock verapamil and
other phenylalkylamines. To elaborate a structural interpretation of the experimental data, we
have built homology models of the open-state channel and its mutants and used Monte Carlo-
energy minimizations to optimize the geometry of the channels and dock verapamil and
emopamil. Our calculations predicted that in the channel with the native residue A^{11}, the
ammonium group of verapamil would donate an H-bond to the backbone carbonyl of T^{p48} at
the C-end of P-helix, the bulky pentanenitrilephenyl moiety would bind in the inner pore
extending towards the cytoplasm, while ring B would enter the intrasubunit niche between
the S6 and P helices with para- and meta-methoxy groups approaching, respectively, the
sidechains of A^{11} and M^{p47}. In the model with the engineered C^{11}, the latter obstructed the
entrance to the intrasubunit niche from the inner pore. Verapamil in this channel model
adopted another binding mode with the ammonium group at the focus of P-helices and the
para-methoxy group in ring B approaching C^{11}. Our modelling further predicted that
emopamil can form an H-bond N-H---S with the cysteine, extend its ring B in the intersubunit
niche, and expose ring A with the isopropyl group to the central cavity. Two emopamil
molecules could easily bind in such modes. The hydrophobic intersubunit niche appears too
small and unattractive for the methoxylated ring B of verapamil or devapamil (Fig. 1), an
analogue of verapamil that exhibits the highest Kv1.3-blocking potency among
phenylalkylamines tested by Dreker and Grissmer (2005). Our study rationalizes structure-
activity of phenylalkylamines in Kv1.3, and highlights the role of inter- and intra-subunit
niches as ligand-binding loci.
Materials and Methods

Designation of residues and mutants. In this study we designate residues using a universal labelling scheme (Zhorov and Tikhonov, 2004), which is described in Figure 2A and respective Figure legend. Since the universal scheme needs explanations, we use traditional residue numbers in the title and abstract. Relations between the residue labels and numbers are shown in Figure 2A. A mutant is designated using a one-letter code for the amino acid in the wild-type channel, its substitution in the mutant channel, and the position label as a superscript between the encoded amino acids.

Cells. The COS 7 cell line was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ No.: ACC 60). Cells were maintained in Dulbecco’s Modified Eagle Medium (D-MEM) with high glucose (Invitrogen, Cat.-No. 41966) containing 10% FCS (PAA Laboratories GmbH, Cat.-No.: A15-041) and cultured at 37°C and 5% p(CO2).

Chemicals and solutions. All measurements were performed in an extracellular bath solution containing (in mM) NaCl 160, CaCl2 2, MgCl2 1, KCl 4.5 and HEPES 5, with an osmolarity of 290-320 mOsm and pH adjusted to 7.4 with NaOH. The intracellular pipette solution contained (in mM) KF 155, MgCl2 2, EGTA 10 and HEPES 10 with an osmolarity of 290-320 mOsm and pH adjusted to 7.2 with KOH. Emopamil (a generous gift from Prof. Dr. Hans-Günther Knaus and Prof. Dr. Hartmut Glossmann, Institut für Biochemische Pharmakologie, Medizinische Universität Innsbruck, Austria) was dissolved in DMSO as stock-solution and diluted to the final concentration in the extracellular bath solution before application. The DMSO fraction in the final solution was always <2%.

Electrophysiology. The whole-cell recording mode of the patch-clamp technique (Hamill et al., 1981) was used throughout all measurements. Drug effects were evaluated by the
steady state current block obtained during 200 ms voltage steps from -80 mV to +40 mV every 30 s at room temperature (18-22°C). Electrodes were pulled from glass capillaries (Science Products, Hofheim, Germany) in three stages and fire-polished to resistances of 2-4 MΩ. Data were acquired with an EPC-9 patch-clamp amplifier (HEKA elektronik, Lambrecht, Germany) connected to a PC running Pulse/Pulse Fit v8.47 data acquisition and analysis software. All currents were filtered by a 2.9 kHz Bessel Filter and recorded with a sampling frequency of 2.00 kHz. Capacitative and leak currents were subtracted.

Molecular biology. The hKv1.3 mutant channels were generated by introducing point mutations in the hKv1.3 wildtype gene contained in a pRc/CMV plasmid vector (a generous gift from Prof. Dr. O. Pongs, Institut für Neurale Signalverarbeitung, Zentrum für Molekulare Neurobiologie, Hamburg, Germany) and confirmed by sequencing. Expression of the mutant genes in COS 7 cells was accomplished by co-transfection of ~1 µg plasmid DNA and ~0.5 µg eGFP-N1 DNA (CLONTech) using Fugene 6 (Roche Molecular Biochemicals) as transfection reagent. One day after transfection sufficient protein levels for electrophysiological measurements were obtained.

Energy calculations. Available x-ray structures of K⁺ channels show different number of K⁺ ions in the selectivity filter: two in the KcsA-antibody complex at low K⁺ concentration (Doyle et al., 1998; Zhou et al., 2001a), three in KcsA (Doyle et al., 1998), and four in KvAP (Jiang et al., 2003), in the KcsA-antibody at high K⁺ concentration (Zhou et al., 2001a), in KcsA blocked by tetrabutylammonium (Zhou et al., 2001b) and in Kv1.2 (Long et al., 2005). We numbered the sites for K⁺ in the selectivity filter from 1 to 4 starting from the most extracellular site. Only two K⁺ ions reside in the selectivity filter simultaneously, suggesting K⁺ oscillation between positions 1/3 and 2/4 (Morais-Cabral et al., 2001; Zhou and MacKinnon, 2003). Previously we have shown that d-tubocurarine interacts most preferably
with the model in which K⁺ ions occupy sites 1 and 3 (Rossokhin et al., 2006). In this study we used the same configuration.

The Monte Carlo-energy minimization (MCM) method (Li and Scheraga, 1987) was used to optimize the Kv1.3 model and to dock the drugs. Energy was minimized in the space of generalized (internal) coordinates using the ZMM program (Zhorov, 1981) (http://www.zmmsoft.com). The generalized coordinates included torsional angles of the channel and ligands, bond angles of ligands, Cartesian coordinates of ions, and variables that govern rigid-body positions and orientations of ligands, water molecules, and the channel subunits. Nonbonded interactions were calculated using the AMBER force field (Weiner et al., 1984; Weiner et al., 1986) with a cutoff distance of 9 Å. Electrostatic interactions and solvation energy were calculated with solvent exposure- and distance-dependent dielectric function (Garden and Zhorov, 2010). Since the protonation state of ionizable residues and location of counterions for ionized residues are unknown, we considered all ionizable residues in their neutral forms (Lazaridis and Karplus, 1999; Momany et al., 1975). The atomic charges of the protonated (R)-verapamil and (R)-emopamil were calculated by AM1 method (Dewar et al., 1985) using program MOPAC. Bond angles at all heavy atoms of the ligands were allowed to vary during energy minimization.

Homology models. In this study we did not address the effect of mutation H₇₅₆T, which retards C-type inactivation, on the P-domain geometry. Since low micromolar concentrations of verapamil block the wildtype Kv1.3 (Rauer and Grissmer, 1996) and its H₇₅₆T mutant (Dreker and Grissmer, 2005), this mutation is unlikely to affect dramatically the drug binding region. Therefore, all calculations were performed using homology models with the wildtype residue H₇₅₆. The x-ray structure of Kv1.2 in the open state (Long et al., 2005) was used as template to build homology models of the wildtype Kv1.3 and its mutant. The A₁₁₁C mutant was calculated with and without the disulfide bond between C₁₁₀ and C₁₁₁. The models were
intensively MC-minimized using the advantage of the four-fold symmetry of the channel, which has been found highly efficient in constraints-driven large-scale modifications of the Shaker channel models (Bruhova and Zhorov, 2005). In calculations with the four-fold symmetry, the pore axis coincided with the z-axis of the Cartesian coordinate system. Torsional angles were sampled in only one subunit (called a parent subunit) and images of the remaining three subunits arranged symmetrically around the pore axis were generated. During MC-minimizations, any change of a torsional angle in the parent subunit, caused identical changes of the same torsional angle in the three images. Intrasubunit interactions were calculated only within the parent subunit, but all intersubunit interactions and interactions of each subunit with potassium ions and water molecules were considered. The symmetric models were optimised in two stages. At the first stage, pin constraints were used to preserve the channel folding that could be distorted by strong repulsions between sidechains in the homology model. (A pin is a penalty function that allows a penalty-free deviation of the respective atom up to 1 Å from the template and imposes an energy penalty for larger deviations.) After the first round of MC-minimizations, all constraints were removed and the model was refined in the second MCM trajectory. In both stages, MC-minimizations were terminated when the last 2,000 energy minimizations did not improve the energy of the apparent global minimum.

Ligand docking. The advantage of the channel symmetry cannot be used for docking of asymmetric ligands. This docking was performed with the channel torsions sampled independently in the four subunits. Unbiased docking of highly flexible ligands like phenylalkylamines in flexible proteins remains a challenge for methodology of global minimization as well as for force fields, which should ensure a match between the global minimum of the free energy and the experimental structure. In view of these challenges, we did not attempt unbiased large-scale search for the lowest-energy binding modes, but used
experimental data to bias location of certain phenylalkylamine moieties in potential ligand-binding loci and optimized the constraint-imposed binding poses by MC-minimizations. Importantly, after finding the lowest-energy conformation in a constrained MCM trajectory, all constraints were removed and another MCM search for the lowest-energy complex was performed. If the unconstrained trajectory caused a noticeable displacement of the ligand from the constraint-imposed binding mode, the corresponding binding mode was disregarded. Each docking experiment involved three MCM trajectories. At the first trajectory, the targeted position of the ligand was imposed by a distance constraint with specific residues, backbone torsions and ligand bond angles kept rigid, while the ligand position, orientation, conformation and protein sidechain conformations were optimized. At the second trajectory, ten lowest-energy structures found in the first trajectory were MC-minimized with all degrees of freedom (including those governing positions and orientation of potassium ions and water molecules) allowed to vary. At the third trajectory, all drug-channel constraints were removed and the ten lowest-energy complexes found in the second trajectory were MC-minimized.

Results

Disulfide bonding bent S6s in the A^{111}C mutant model. The point mutation A^{111}C dramatically decreases the channel-blocking potency of verapamil and other phenylalkylamines with the methoxylated ring B (Dreker and Grissmer, 2005). Two explanations for this observation can be proposed. First, the bulky engineered cysteine at the interface between the P-helix and the S6 helix may hinder binding of a phenylalkylamine moiety in the intra- or inter-subunit niche. Second, the point mutation may cause non-local
conformational changes of the channel protein. A point mutation normally is not expected to substantially change the backbone geometry. However, sequentially adjacent cysteines may form disulfide bonds (Zhang and Snyder, 1989) that would distort the backbone. To estimate possible distortions, we MC-minimized three models: the wildtype Kv1.3 channel, the A^11-C mutant with the disulfide bonds C^10-C^11 in all four subunits, and the A^11-C mutant without the disulfide bonds. In the model with the disulfide bonds the subunit interface viewed along the P-helix is substantially wider than in the wildtype channel (cf. Figs. 2A and B). In this model, S6 helices were substantially deformed. These deformations can be easily explained by the fact that the distance between beta carbons of the adjacent disulfide-bonded cysteines C^10 and C^11 (4.07 Å) is 1.17 Å smaller than in the A^11-C mutant model without the disulfide bonds (5.24 Å). Such a substantial decrease of the distance between beta-carbons can be achieved only due to deformation of backbone torsions. These torsional deformations should shift parts of the alpha helix on both sides of the disulfide bridge. When compared with the wild-type channel model (Fig. 2B), only the C-terminal parts of S6s in the disulfide-bonded model shifted substantially. A shift of the N-terminal third of S6 was opposed by a knob-into-hole contact between G^13 and Val in the AVY motif at the C-end of S5. In the A^11-C mutant model without the disulfide bonds, the inner helices only minimally rearranged versus the wildtype Kv1.3 model (Figs. 2B and D).

The widened hydrophobic interface between neighbouring S6 helices in the A^11-C mutant might accommodate a part of the ligand and thus explain binding of two emopamil molecules to the channel. However, it is unknown whether C^10 and C^11 are engaged in the disulfide bond. To address this question, we have generated a triple mutant and explored the stoichiometry of emopamil binding as described below. Our rational for a triple mutant instead of a different double mutant is that phenylalkylamines bind to the channel with A^11 much stronger than to the channel with C^11. Introducing another mutation at this position
would result in either a strong binding or a weak binding or something in between. This would not really help in testing the hypothesis on the disulphide bond formation.

Similar electrophysiological properties of $H^{p56T}$, $H^{p56T/Ai11C}$ and $H^{p56T/Ci10A/Ai11C}$ channels. To explore whether the newly generated triple-mutant channel ($H^{p56T/Ci10A/Ai11C}$) of $hKv1.3$ has a dramatically altered behavior we performed a detailed characterization of the electrophysiological properties of the triple mutant channel and compared these properties with those for the single ($H^{p56T}$) and the double ($H^{p56T/Ai11C}$) mutant channels. The comparison is shown in Fig. 3 for the voltage-dependence of activation (Fig. 3A,C,E) and for the use dependence of inactivation (Fig. 3B,D,F). The current traces of the double and triple mutant look very similar indicating that these channels did not dramatically differ from each other. A summary of the intrinsic properties of the $hKv1.3$ wild type and mutant channels is further shown in Table 1.

Similar block of $H^{p56T/Ai11C}$ and $H^{p56T/Ci10A/Ai11C}$ channels by emopamil. To explore whether the mutation $Ai11C$ affects ligand action directly or indirectly, via formation of the disulfide bonding between $Ci10$ and $Ci11$, we compared the emopamil stoichiometry in the double and triple mutants. We reasoned that if the Hill coefficient of emopamil binding in the $Ai11C$ mutant increases due to S6 deformations caused by the disulfide bonding, the disulfide-bond elimination in the triple mutant would restore the 1:1 emopamil stoichiometry as in the C-type inactivation reduced $hKv1.3_H^{p56T}$ channels that we explored before (Dreker and Grissmer, 2005). Figure 4A shows steady-state $K^+$ currents through single-mutant $hKv1.3_H^{p56T}$ channels in the absence (control) and presence of 20 µM emopamil. 20 µM emopamil resulted in a steady-state block of current through $hKv1.3_H^{p56T}$ channels at the end of the 200 ms pulse to less than 10% of the control current. This directly reflects the ratio of $hKv1.3_H^{p56T}$ channels in the open and open-blocked state. Using different
emopamil concentrations we could generate a dose-response curve for emopamil to block steady-state currents at the end of a 200 ms depolarizing voltage step (Fig. 4B) as published (Dreker and Grissmer, 2005). A fit to the data (solid line) indicated that one emopamil molecule binds reversibly to one mutant channel (Hill coefficient close to 1) thereby preventing current flow with an IC₅₀ value for emopamil to block steady state current of the mutant hKv1.3_H₅₆T channel of 2 µM. The double mutant hKv1.3_H₅₆T/A₁₁₁C channel is much less sensitive to block by emopamil as can be seen in Fig. 5A. 20 µM emopamil resulted in a steady state block of current through the double mutant hKv1.3_H₅₆T/A₁₁₁C channels at the end of the 200 ms pulse to ~80% of the control current. Similar results have been obtained earlier (Dreker and Grissmer, 2005). In addition, emopamil blocked current through the double mutant hKv1.3_H₅₆T/A₁₁₁C channel with a 2:1 stoichiometry as can be seen in the dose-response curve shown in Fig. 6.

To test whether possible disulfide bonds between C₁₁₀ and C₁₁₁ contribute to the observed changes in affinity and stoichiometry of emopamil block in the double mutant, we generated a triple-mutant hKv1.3_H₅₆T/C₁₁₀A/A₁₁₁C channel and investigated the effects of emopamil on current through this triple mutant channel. The results are shown in Fig. 5B. Application of 20 µM emopamil resulted in a steady state block of current through the triple mutant hKv1.3_H₅₆T/C₁₁₀A/A₁₁₁C channels at the end of the 200 ms pulse to ~80% of the control current. This result is almost identical to the results obtained for the effect of emopamil on the double mutant hKv1.3_H₅₆T/A₁₁₁C channel. Likewise, the stoichiometry for emopamil to block current through the triple mutant channel (dose-response curve in Fig. 6) is almost identical to that for the double mutant channel.
Docking of verapamil and emopamil in the wildtype Kv1.3 and A^{111}C mutant

The above experimental data ruled out a possibility that mutation A^{111}C decreases potency of phenylalkylamines with the para-methoxy group in ring B and increases stoichiometry of the channel block by emopamil through distortion of the inner helices due to formation of a disulfide bond C^{10}-C^{11}. The alternative hypothesis is that the mutation A^{111}C decreases potency of verapamil and other phenylalkylamines with the para-methoxy group in ring B because the latter clashes with the bulky sidechain of the engineered cysteine C^{11}. This hypothesis provides an important distance constraint to dock verapamil in the wildtype and mutated channels.

We used a distance constraint to impose the para-oxygen in ring B of verapamil to be within 6 Å from the beta-carbon of A^{111}. Such a large distance was chosen to impose no specific contacts, but just to bring the para-oxygen in proximity of A^{111}. MC-minimization of the complex in the presence of the constraint, and then the refinement MC-minimization without constraints predicted two low-energy binding modes. In the lowest-energy model (Fig. 7 A-D), the ammonium group donated an H-bond to the backbone carbonyl of T^{p48}. This carbonyl at the P-loop turn does not accept an H-bond from the upstream backbone amides and therefore constitutes an attractive acceptor for an H-bond from the ligand. In this binding mode, a large part of ring B entered the intra-subunit niche with the meta- and para-methoxy groups approaching the sidechains of M^{p47} and A^{111}, respectively (Fig. 7 C).

In the second-best model in terms of ligand-channel energy, the ammonium group of verapamil occurred at the focus of the P-helices, the meta-methoxy groups approached the intra-subunit niche between S6 and the P-helix, and the para-methoxy group entered the inter-subunit niche between two inner helices and approached the methyl group of A^{111} without establishing strong contacts with it (Fig. 7 F). The verapamil-channel energy in this model is ~1.6 kcal/mol higher (less favourable) than in the first model, but this difference is
not large enough to choose one of the models basing on energetics only. The second binding mode is consistent with the data that N-methyl-verapamil blocks Kv1.3 with the potency similar to that of verapamil (Rauer and Grissmer, 1996). Indeed, the focus of the P-helices is rather far from any residue of the channel and would easily accommodate the quaternary ammonium group of N-methyl-verapamil, which cannot donate an H-bond. This fact, however, does not rule out a possibility that verapamil donates an H-bond to the backbone carbonyl of Tp48 as shown in Fig. 7 B,C because similar potencies of verapamil and N-methyl-verapamil may result from two binding modes shown in Fig. 7, which have many common features. The advantage of the first model is the penetration of ring B in the intrasubunit niche and therefore a closer proximity of the meta-methoxy group in ring B to Mp47. This methionine in position p47 is proposed to contribute to the verapamil binding site because the mutation M47V decreases verapamil potency (Rauer and Grissmer, 1999).

MC-minimization of verapamil in the A11C mutant channel from the starting points that correspond to both binding modes shown in Fig. 7 yielded structures with weaker channel-ligand energy because the bulky sidechain of cysteine C11 clashes with the para-methoxy group (not shown).

Binding of two emopamil molecules in the modes shown in Fig. 7 is not possible because the focus of the P-helices cannot accommodate two ammonium groups. MC-minimization of Kv1.3 with two emopamil molecules from the starting point shown in Fig. 7A,C yielded a model with the ammonium groups of two emopamil molecules donating H-bonds to two carbonyls of Tp48, but the ligand-channel energies for each ligand were significantly higher (weaker interactions) than that for verapamil because the inner pore is not large enough to accommodate two pentanenitrilephenyl moieties from two ligands.

Intensive MC-minimization of Kv1.3 with a single emopamil resulted in a complex in which the ligand ammonium group donated an H-bond to the sulphur atom of C11. Such
binding mode is possible only when the ring B of the ligand deeply penetrates in the
intersubunit niche. The channel easily accommodated two emopamil molecules bound in
such a mode (Fig. 8A, B), while pentanenitrilephenyl moieties of the two ligands established
favourable hydrophobic contacts with each other (Fig. 8C). Importantly, all residues around
the hydrophobic phenyl ring B of emopamil are hydrophobic (Fig. 8D). Furthermore, ring B
fits tightly in the inter-subunit niche, while the para- and/or meta-methoxy substituents
would sterically clash with the bulky hydrophobic residues there. These features of the
model shown in Fig. 8 readily explain why emopamil but not phenylalkylamines with the
methoxylated ring B block Kv1.3 with the 2:1 stoichiometry.
Phenylalkylamines constitute a promising class of blockers of the medicinally important Kv1.3 channels. Previous studies revealed interesting structure-activity relationships of phenylalkylamines in the C-type inactivation-reduced mutant \( hKv1.3_H^{P56-T} \) and the double mutant \( hKv1.3_H^{P56-T/A^{i11}} \). The most challenging paradox is the different stoichiometry of the channel block by verapamil and devapamil on one hand and demethoxylated emopamil on the other hand. Previously proposed qualitative rationale for this paradox (Dreker and Grissmer, 2005) lacks atomistic details. Our initial attempts to elaborate these details by means of molecular modeling suggested different mechanistic explanations for the experimental data: (i) the substantial deformation of the inner helices due to possible disulfide bonding between native C\(^{i10}\) and engineered C\(^{i11}\) and/or (ii) the direct interactions of phenylalkylamines with the sidechain of C\(^{i11}\). To choose between these mechanisms we generated here a triple mutant \( hKv1.3_H^{P56-T/C^{i10-A^{i11}}} \) in which disulfide bonding between the neighbouring inner-helix residues is impossible and therefore substantial deformations of the inner helices are unlikely. The fact that stoichiometry and other characteristics of emopamil action in the triple mutant occurred similar to those in the double mutant ruled out the first mechanism and allowed us to focus on the second mechanism.

The unbiased predictive docking of flexible ligands in proteins remains a challenge even when using a simplified computational approach, when a protein is treated as a rigid body. Currently this methodology cannot guarantee that an apparent global minimum found in energy calculations corresponds to the experimental structure found by the x-ray crystallography (Garden and Zhorov, 2010). Expectations that the native structure of a ligand-channel complex would correspond to an apparent global minimum found by hands-
free docking of such a flexible ligand as verapamil in a homology model of the channel with flexible sidechains would be overoptimistic at least. On the other hand ligand docking is the only currently available methodology that could be used as a substitute for extremely difficult and in most cases hardly doable crystallographic analyses of channel-ligand complexes. A solution for this dilemma is to use experimental data as constraints in energy calculations. Importantly, a structure proposed by the constraints-driven docking should remain stable upon subsequent relaxation by Monte Carlo minimization (or molecular dynamics) without any constraints. Relaxation by simple energy minimization cannot be used to estimate the model stability because the energy landscape is extremely rugged and constraints may cause the system to be trapped in a high-energy local minimum from which it is not possible to find an exit by simple energy minimization. The ligand-protein energy of the refined relaxed system should be negative and furthermore, the partitioned energy contributions of all residues, which are in direct contact with the ligand, should also be negative to indicate the absence of sterical clashes. Whether or not the energy of the active complex predicted in a homology model (which is obviously less precise than a high-resolution x-ray structure) corresponds to the apparent global minimum is less important. However, if the predicted active complex corresponds to a local energy minimum, its energy should not be substantially higher (no more than 4 kcal/mol in our studies) than the energy of the apparent global minimum. It should be noted that models shown in Figs. 7 and 8 satisfy all these criteria.

Results of our constraints-driven docking provide structural explanations for available data on action of phenylalkylamines in hKv1.3 and its mutants. Important characteristics of the predicted complexes are the binding of the ammonium group to a cationophilic site in the cavity, the proximity of ring B to the P-loop turn, and the extension of the bulky pentanenitrilephenyl moiety along the inner pore, towards the cytoplasm. We did not find any specific interactions of the cyano group with the channel, in agreement with the
observations that the IC₅₀ value for the steady-state block of hKv1.3_H₅₆T by (±)-acyanoverapamil is similar to that of (±)-verapamil (Dreker and Grissmer, 2005).

Our results suggest that ring B of the phenylalkylamines binds in the intrasubunit niche of Kv1.3, while this niche in the Aᵢ₁¹C mutant is obstructed by the cysteine sidechain. Only the demethoxylated phenyl ring B of emopamil can penetrate the intersubunit niche of the mutant. In a model of devapamil in the Caᵥ₁.₂ channel intra- and inter-domain interfaces constitute binding loci for rings A and B, respectively (Cheng et al., 2009). Why does ring B of devapamil bind between helices 3P and 4S6 in Caᵥ₁.₂, but does not bind between respective helices in Kv1.₃? There may be two possible reasons for this. First, in the Caᵥ₁.₂ channel model, Y₄ᵵ₁ injects an H-bond to the meta-methoxy group in ring B of devapamil, while Kv1.₃ contains Aᵢ₁¹ in the respective position. Second, several bulky residues in the intersubunit niche of Kv1.₃ (Fig. 8D) have less bulky analogues in the Caᵥ₁.₂ channel (Table 2).

The inter- and intra-subunit niches can be seen in surface images of the channel with the ligands that extend their moieties to the niches (Figs. 8E, 7D). While the intra-subunit niche (Fig. 7D) appears smaller than the inter-subunit niche (Fig. 8E) the former can accommodate a part of ring B. The sidechains of Aᵢ₁¹ and M₄₄₇ do not occlude the entrance to the niche because the Cᵦ-Cᵧ bonds of these residues extend along the niche walls (Fig. 2G,F). Bonds Aᵢ₁¹-Cᵦ-Cᵧ and M₄₄₇-Cᵦ-Cᵧ direct towards the pore and away it, respectively. The flexible sidechain of M₄₄₇ can adopt conformations in which atoms Sᵧ and/or Cᵧ can approach the meta-methoxy group of verapamil to contribute to its binding pocket. This explains why the mutation M₄₄₇V decreases Kv1.₃-blocking potency of verapamil sixfold (Rauer and Grissmer, 1999). The sidechains of T₄₈₈ and T₄₉₉ do not contribute to verapamil binding in our models in agreement with data that mutations T₄₈₈S and T₄₉₉A do not cause noticeable effects on Kv1.₃ block by verapamil (Rauer and Grissmer, 1999).
The important and rather unexpected prediction of our calculations is the H-bonding of the ammonium group of emopamil to the sulfur atom of C^{i11}. Parameters for the NH⋯S H-bonds are present in the earlier version of the AMBER force field that is implemented in the ZMM program. The ability of sulfur to accept H-bonds has been demonstrated from analysis Cambridge Structural Database (Allen et al., 1997). H-bonds N-H⋯S were found in crystals of small molecules (Chung et al., 1991). In the x-ray structure of Mycobacterium tuberculosis LipB enzyme (PDB code 1w66) the distance between the lysine sidechain N and the cysteine S is as small as 3.42 Å (Ma et al., 2006). The formation of strong N-H---S bonds was recently demonstrated experimentally and by high-level computations (Biswa and Wategaonkar, 2009).

In conclusion, this study explains the intriguing peculiarities of structure-activity relationships of phenylalkylamines interacting with Kv1.3 channels and its A^{i11}C mutant proposing atomistic details for the channel block by this important class of ligands.

Acknowledgements
We thank Daniel Garden for PYMOL images shown in Fig. 7D and 8E.

Authorship Contributions
Participated in research design: Rossokhin, Dreker, Grissmer, and Zhorov.
Conducted experiments: Rossokhin, Dreker, and Zhorov.
Performed data analysis: Rossokhin, Dreker, Grissmer and Zhorov.
Wrote or contributed to the writing of the manuscript: Rossokhin, Dreker, Grissmer and Zhorov.
Other: Grissmer and Zhorov acquired funding for the research.
References


Footnotes

* These authors contributed equally to the study

# Senior authors

Computations were made possible by the facilities of the Shared Hierarchical Academic Research Computing Network (SHARCNET:www.sharcnet.ca). This work was supported by grants from Natural Sciences and Engineering Research Council of Canada, the Deutsche Forschungsgemeinschaft [Gr 848/14 1] and 4SC AG (Martinsried, Germany).
Figure Legends

Figure 1. **Structural formulae of verapamil, devapamil, and emopamil.**

Figure 2. **Inter- and intra-subunit interfaces in the Kv1.3 channel and its mutants.**

A, Human Kv1.3 pore domain sequence. Special symbols mark helices (=), loops/turns (~), and the selectivity-filter region (^). Residue labels and numbers are shown above the respective residues. A label consists of a segment-encoding character and the relative number of the residue in the segment. Character k stands for a linker L45, o for an outer helix (S5), p for a P-loop, and i for an inner helix (S6). B-E, Intersubunit interface in the homology model of the wildtype Kv1.3, which contains the dipeptide fragment C_{i10}^{i10} - A_{i11}^{i11} (B), in the mutant A_{i11}^{i11}C without (D) and with (C) disulfide bond between the adjacent cysteines C_{i10}^{i10} - C_{i11}^{i11}, and in the triple mutant C_{i10}^{i10}A / A_{i11}^{i11}C, which contains the dipeptide fragment A_{i10}^{i10} - C_{i11}^{i11} (E). The models are viewed along the pore helix of magenta-colored subunit. Only S6s and the P-loops in two neighboring segments are shown for clarity. Cysteine residues are space-filled. Note different dimensions of the space between two S6s and the P-loop. The tiny yellow balls are potassium ions. F-G, Intra-subunit interface between the S6 and P-helices in the x-ray structure of the Kv1.2 channel with the residues in the interface shown as sticks. F, Side view. G, View from inside the pore, along the P-helix. The S6 side of the interface has C_{i10}^{i10}, A_{i11}^{i11}, and G_{i14}^{i14}. The P-helix side contains T_{p46}^{p46} and M_{p47}^{p47}. The entrance to the interface from the inner pore is guarded by small A_{i11}^{i11} and the flexible-sidechain M_{p47}^{p47}. The tiny yellow balls are potassium ions.
Figure 3. **Currents through single (H<sup>p56</sup>T), double (H<sup>p56</sup>T/A<sup>i11</sup>C), and triple (H<sup>p46</sup>T/C<sup>i10</sup>A/A<sup>i11</sup>C) mutant hKv1.3 channels.** *A,C,E.* I/V relationship of currents through single (*A*), double (*C*), and triple (*E*) mutant hKv1.3 channels. The displayed currents were induced by consecutive 200 ms voltage pulses from the holding potential of -80 mV to potentials ranging from -50 mV to +50 mV with an increment of 10 mV for each pulse. *B,D,F.* Use-dependency of currents through single (*B*), double (*D*), and triple (*F*) mutant hKv1.3 channels. The displayed currents were induced by 10 consecutive 200 ms voltage pulses from the holding potential of -80 mV to +40 mV every s.

Figure 4. **Effect of extracellularly applied emopamil on steady-state current** through mutant hKv1.3<sub>_H<sup>p56</sup>T</sub> channels. *A,* Currents were elicited by 200 ms depolarizing voltage steps from a holding potential of −80 to +40 mV every 30 s in the absence (control) and presence of 20 µM emopamil. Shown are steady-state currents in the two solutions. *B,* Dose-response curve for emopamil block of steady-state currents through hKv1.3<sub>_H399T</sub> mutant channels. Curve-fitting resulted in an IC<sub>50</sub> value of 2.0 µM and a Hill coefficient of 0.8 (data from Dreker and Grissmer, 2005).

Figure 5. **Effect of extracellularly applied emopamil on steady-state current** through the double (*A*, H<sup>p56</sup>T/A<sup>i11</sup>C) and the triple (*B*, H<sup>p46</sup>T/C<sup>i10</sup>A/A<sup>i11</sup>C) mutant hKv1.3 channels. Currents were elicited by 200 ms depolarizing voltage steps from a holding potential of −80 to +40 mV every 30 s in the absence (control) and presence of 20 µM emopamil. Shown are steady-state currents in the two solutions.
Figure 6. **Dose-response curve for emopamil block of steady-state currents** through the double (blue, H\(^{p56}\)T/A\(^{i11}\)C) and the triple (red, H\(^{p56}\)T/C\(^{i10}\)A/A\(^{i11}\)C) mutant \(hKv1.3\) channels. Data points at each concentration from at least two independent measurements. Curve-fitting resulted in an IC\(_{50}\) value of 36 \(\mu\)M with a Hill coefficient of 2.2 for the double mutant \(hKv1.3_{-H^{p56}T/A^{i11}C}\) channel and an IC\(_{50}\) value of 42 \(\mu\)M with a Hill coefficient of 2.2 for the triple mutant \(hKv1.3_{-H^{p56}T/C^{i10}A/A^{i11}C}\) channel, respectively. The dose-response curve for emopamil block of steady-state currents through \(hKv1.3_{-H^{p56}T}\) mutant channels (from Fig. 3B) was included in this graph for comparison.

Figure 7. **Verapamil binding in the inner pore of Kv1.3.** Shown are extracellular (A), side (B, D, E), and close-up (C, F) views at predicted binding modes along the red arrows in B and E, respectively. For clarity, one subunit is removed in B and E and two subunits are removed in D. In all panels, except D, the P-helices and the inner helices are shown as smooth helices, the outer helices and the L45 linkers as thin helices, the ascending limbs in the outer pore and the extracellular linkers as rods. Three subunits are colored cyan and one subunit is colored green. \(K^+\) ions, water molecules, and the sidechains of M\(^{p47}\) and A\(^{i11}\) are space-filled. A-D. The first binding mode in which verapamil (orange carbons) donates an H-bond to the backbone carbonyl of T\(^{p48}\) (C) while ring B extend into the intra-subunit niche. The latter is seen in the surface representation (D) where S5, P-loop, and S6 of one subunit are dark green, yellow, and light green, respectively, and S6 of the neighboring subunit is cyan. E and F. In the second binding mode the ammonium group of verapamil is located at the focus of the P-helices. In both binding modes, the \(p\)-methoxy group in ring B approaches the methyl group of A\(^{i11}\), while the \(m\)-methoxy group approaches the sidechains of M\(^{p47}\).
Figure 8. **Model of the Kv1.3 mutant A<sup>110</sup>C with two emopamil molecules.** The ligands’ ammonium groups donate H-bonds to the sulfur atoms of C<sup>110</sup>, while the aromatic rings B hide in the hydrophobic niches. Sidechains of C<sup>110</sup> and C<sup>111</sup> are space-filled at A-C. **A,** Side view with two subunits removed for clarity. **B,** Extracellular view in which two subunits are colored green and two subunits are cyan. **C,** Close-up cytoplasmic view along the red arrow shown in **A.** Note close contacts between the aromatic and the isopropyl groups of the two ligands that would make the pore impermeable. **D,** View along the P-helix along the red arrow indicated in **B.** Sidechains of the hydrophobic residues, which are located in the interface between subunits within 5 Å from ring B of the emopamil molecule, are shown by sticks. The aromatic ring of emopamil fits snugly in the hydrophobic interface, while the methoxylated ring of verapamil would experience sterical clashes and unfavourable dehydration. **E,** Surface representation with the channel segments coloured as in Fig. 7D. The intersubunit niche accommodates ring B of emopamil.
Table 1. Intrinsic properties of the hKv1.3 wild type channel and the single (H\(^{p56T}\)), double (H\(^{p56T/A11C}\)), and triple (H\(^{p56T/C10A/A11C}\)) mutant channels transiently transfected in COS7 cells. All values are given as mean ± s.d.; numbers of independent experiments are given in parentheses. Values for the wild type, the single and the double mutant channels are from Dreker and Grissmer (2005).

<table>
<thead>
<tr>
<th>Properties</th>
<th>hKv1.3 channel and its mutants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wild Type</td>
</tr>
<tr>
<td>(V_{1/2}) (mV)</td>
<td>-33 ± 1 (2)</td>
</tr>
<tr>
<td>(k) (mV)</td>
<td>10 ± 1 (2)</td>
</tr>
<tr>
<td>(\tau_m) (ms)</td>
<td>2.9 ± 0.4 (6)</td>
</tr>
<tr>
<td>(\tau_h) at +40 mV (ms)</td>
<td>291 ± 53 (6)</td>
</tr>
<tr>
<td>(\tau_t) at -60 mV (ms)</td>
<td>117 (1)</td>
</tr>
<tr>
<td>(\tau_{rec}) at -120 mV (s)</td>
<td>13.6 ± 0.2 (4)</td>
</tr>
</tbody>
</table>
Table 2. Residues in the intersubunit niche of the Kv1.3 channel versus matching residues in the Ca_{1.2} channel

<table>
<thead>
<tr>
<th>Channel</th>
<th>Residue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kv1.3</td>
<td>L'^10</td>
</tr>
<tr>
<td></td>
<td>I'^11</td>
</tr>
<tr>
<td></td>
<td>L'^14</td>
</tr>
<tr>
<td></td>
<td>I'^18</td>
</tr>
<tr>
<td></td>
<td>V'^22</td>
</tr>
<tr>
<td></td>
<td>I'^12</td>
</tr>
<tr>
<td></td>
<td>V'^15</td>
</tr>
<tr>
<td>Ca_{1.2}</td>
<td>I'^3010</td>
</tr>
<tr>
<td></td>
<td>V'^3011</td>
</tr>
<tr>
<td></td>
<td>T'^3014</td>
</tr>
<tr>
<td></td>
<td>M'^315</td>
</tr>
<tr>
<td></td>
<td>F'^3122</td>
</tr>
<tr>
<td></td>
<td>M'^412</td>
</tr>
<tr>
<td></td>
<td>A'^415</td>
</tr>
</tbody>
</table>
Figure 1

Verapamil

Devapamil

Emopamil
Figure 2
Figure 3

A  hKv1.3_Hp56T  
I, V relation

B  hKv1.3_Hp56T  
use dependence

C  hKv1.3_Hp56T/Ai11C  
I, V relation

D  hKv1.3_Hp56T/Ai11C  
use dependence

E  hKv1.3_H3p56T/Ci10A/Ai11C  
I, V relation

F  hKv1.3_H3p56T/Ci10A/Ai11C  
use dependence
Figure 4

A. hKv1.3_Hp56T

B. hKv1.3_Hp56T

relative steady-state current vs. emopamil (µM)
Figure 5

A

hKv1.3_Hp56T/Ai11C

control

emopamil 20 µM

1 nA

50 ms

B

hKv1.3_H3p56T/Ci10A/Ai11C

control

emopamil 20 µM

1 nA

50 ms

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 6

The graph illustrates the relative steady-state current with respect to emopamil concentration for three different kV1.3 variants:

- **hKv1.3_Hp56T** (closed circles)
- **hKv1.3_Hp56T/A111C** (open triangles)
- **hKv1.3_Hp56T/C110A/A111C** (closed squares)

The x-axis represents the concentration of emopamil in µM, ranging from 0.01 to 1000 µM. The y-axis shows the relative steady-state current.
Figure 8